Thieme E-Books & E-Journals -
Back
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(06): 926-938
DOI: 10.1055/s-0041-1740254
Coagulation and Fibrinolysis

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease

Alexander T. Cohen
1   Department of Hematological Medicine, Guy's & St. Thomas' NHS Foundation Trust, King's College London, London, United Kingdom
,
Janvi Sah
2   SIMR, LLC, Ann Arbor, Michigan, United States
,
Amol D. Dhamane
3   Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States
,
Theodore Lee
4   Pfizer Inc., New York, New York, United States
,
Lisa Rosenblatt
3   Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States
,
Patrick Hlavacek
4   Pfizer Inc., New York, New York, United States
,
Birol Emir
4   Pfizer Inc., New York, New York, United States
,
Rachel Delinger
2   SIMR, LLC, Ann Arbor, Michigan, United States
,
Huseyin Yuce
5   Department of Mathematics, New York City College of Technology, City University of New York, New York, New York, United States
,
Xuemei Luo
6   Pfizer Inc., Groton, Connecticut, United States
› Author Affiliations